Conceptus, Inc. Board of Directors Under Investigation by Glancy Binkow &
Goldberg LLP for Potential Breaches of Fiduciary Duty
LOS ANGELES -- April 29, 2013
Glancy Binkow & Goldberg LLP announces that it is investigating potential
claims against the Board of Directors of Conceptus, Inc. (“Conceptus” or the
“Company”) (NASDAQ:CPTS) related to the proposed acquisition of the Company by
Bayer HealthCare LLC. The transaction is valued at approximately $1.1 billion
or $31 per share.
This investigation concerns whether the Board of Directors of Conceptus
breached their fiduciary duties to stockholders by failing to adequately shop
the Company before agreeing to enter into the proposed transaction, and
whether the Company has disclosed all material information to shareholders
about the transaction. The Company has seen substantial recent growth. Its
share price has skyrocketed from $9.76 on October 3, 2011 to $26.73 on April
If you are a shareholder of Conceptus, if you have information or would like
to learn more about our investigation, or if you wish to discuss these matters
or have any questions concerning this announcement or your rights or interests
with respect to these matters, please contact Louis Boyarsky, Esquire, Glancy
Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, CA
90067, by telephone at (310) 201-9150 or Toll Free at (888) 773-9224 or by
email to firstname.lastname@example.org.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
Glancy Binkow & Goldberg LLP
Louis Boyarsky, Esquire
(310) 201-9150 or Toll Free (888) 773-9224
Press spacebar to pause and continue. Press esc to stop.